Elevated serum levels of vascular endothelial growth factor predict a poor prognosis of platinum-based chemotherapy in non-small cell lung cancer
OncoTargets and Therapy2017Vol. Volume 10, pp. 409–415
Citations Over TimeTop 25% of 2017 papers
Jialan Zang, Yong Hu, Xiaoyue Xu, Jie Ni, Dali Yan, Siwen Liu, Jieyu He, Jing Xue, Jian Wu, Jifeng Feng
Abstract
In conclusion, the serum VEGF levels were found to be a poor prognostic biomarker for the efficacy of platinum-based chemotherapy in terms of PFS, but it was not shown to be a suitable predictive marker for clinical response to platinum-based chemotherapy.
Related Papers
- → Electrochemical biosensors for the detection of lung cancer biomarkers: A review(2019)353 cited
- → Molecular genetics of lung cancer in people who have never smoked(2008)131 cited
- → Molecular Epidemiology of Female Lung Cancer(2011)10 cited
- → [Gender-associated differences of lung cancer and mechanism].(2011)3 cited
- The Expression and Clinical Significance of Adrenomedulin in Patients with Lung Cancer(2006)